U

    Upstream Bio, Inc. (UPB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $6.62
    -0.07 (-1.05%)

    Market Cap: $366.42M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(4/8)
    Avg Surprise
    -9.99%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.70
    Range$-0.88 - $-0.46
    9 analysts
    EPS Revisions
    1
    0
    7d
    3
    2
    30d
    EPS Estimate Drift
    90d ago$-0.68+3.1%
    60d ago$-0.71-1.5%
    30d ago$-0.71-1.3%
    7d ago$-0.70+0.0%
    Current$-0.70
    Revenue Consensus
    $378880
    Range$0 - $875000
    8 analysts
    Dec 31, 2026
    EPS Consensus$-0.69
    Range$-1.05 - $0.05
    9 analysts
    Revenue Consensus
    $1M
    Range$544330 - $2M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.69---
    Sep 26EST
    		-$-0.70---
    Jun 26
    		$-0.73$-0.78+6.41%Beat+1.4%
    Mar 26
    		$-0.75$-0.75+0.00%Beat-47.1%
    Dec 25
    		$-0.78$-0.70-11.43%Miss-90.2%
    Sep 25
    		$-0.63$-0.78+19.23%Beat+90.9%
    Jun 25
    		$-0.74$-0.61-21.31%Miss+93.4%
    Mar 25
    		$-0.51$-0.48-6.25%Miss-
    Dec 24
    		$-0.41$-0.54+24.12%Beat-
    Sep 24
    		$-6.96$-3.65-90.68%Miss-
    Jun 24
    		$-11.18$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-2.29EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-5481.00%
    ROE-46.10%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio27.99xQuick Ratio27.99x
    Trading Statistics
    BetaN/AAvg Volume639.05K
    52-Week High$33.6852-Week Low$5.85

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$6.92
    SMA 20$6.97
    SMA 50$6.93
    SMA 200$14.26
    EMA 10$6.86
    EMA 20$6.90
    EMA 50$7.13
    EMA 200$11.01

    MACD

    Line: -0.03Signal: -0.00Hist: -0.03

    ADX

    ADX: 15.5+DI: 14.8-DI: 20.1

    Aroon & PSAR

    Aroon Up44.0
    Aroon Down4.0
    PSAR$7.24

    Bollinger Bands

    Upper Band$7.48
    Lower Band$6.47
    %B Position1450%(Upper)
    Band Width0.15

    RSI (14-Day)

    Neutral
    45.1

    Momentum Oscillators

    Stoch %K20.4
    Stoch %D33.2
    Williams %R-83.9
    ROC (10d)-7.3%
    Momentum-0.52
    CCI (20d)-153.9
    MFI (14d)40.5

    Volatility Measures

    ATR (14d)$0.43(6.4%)
    StdDev (20d)0.25
    Hist Vol75.4%(High)

    Volume Flow

    VWAP$6.60
    OBV-6.1M
    AD Line-5.8M
    CMF (20d)0.121

    Volume Metrics

    Avg Vol (20d)632.3K
    Vol Ratio1.4x
    VWMA (20d)$6.97

    Pivot Points

    R3$6.98
    R2$6.88
    R1$6.79
    Pivot Point$6.69
    S1$6.60
    S2$6.50
    S3$6.41

    Advanced Oscillators

    TSI-1.99
    Ultimate Osc51.0
    KST5.01

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$773,000$1.03M$668,000$683,000$937,000$566,000$613,000$607,000$510,000$640,000$450,000$621,000
    Cost of Revenue$0$0$57,000$0$0$0$49,000$0$0$0N/A$0
    Gross Profit$773,000$1.03M$668,000$683,000$937,000$566,000$613,000$607,000$510,000$640,000$450,000$621,000
    Operating Expenses$43.14M$44.65M$46.84M$38.52M$45.28M$32.58M$26.93M$19.50M$18.05M$15.65M$14.78M$10.01M
    R&D$36.09M$36.56M$40.17M$32.98M$37.87M$25.80M$21.77M$15.43M$14.07M$11.69M$11.55M$7.79M
    SG&A$7.05M$8.08M$6.67M$5.54M$7.42M$6.78M$5.16M$4.07M$3.98M$3.96M$3.23M$2.22M
    Operating Income$-42,368,000$-43,615,000$-46,167,000$-37,834,000$-44,347,000$-32,013,000$-26,318,000$-18,893,000$-17,540,000$-15,013,000$-14,330,000$-9,386,000
    Interest Income$2.66M$3.05M$3.65M$4.11M$4.43M$4.74M$5.08M$2.90M$2.88M$1.27M$1.52M$1.53M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-39,702,000$-40,591,000$-42,459,000$-33,748,000$-39,966,000$-27,270,000$-21,242,000$-15,992,000$-14,678,000$-10,894,000$-11,833,000$-3,102,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-39,702,000$-40,591,000$-42,459,000$-33,748,000$-39,966,000$-27,270,000$-21,242,000$-15,992,000$-14,678,000$-10,894,000$-11,833,000$-3,102,000
    EBITDA$-42,350,000$-44,350,000$-44,684,000$-37,961,000$-45,340,000$-33,705,000$-25,587,000$-19,454,000$-18,684,000$-12,770,000$-11,819,000$-4,629,000
    EBIT$-42,361,000$-43,645,000$-46,113,000$-37,853,000$-44,397,000$-32,013,000$-26,318,000$-18,896,000$-17,555,000$-12,160,000$-11,833,000$-4,629,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about UPB

    News

    Norges Bank Initiates New Position in Upstream Bio Inc (UPB) with 4.2 Million Share Purchase

    Norges Bank has initiated a new position in Upstream Bio Inc (UPB) by acquiring over 4.2 million shares, representing a 7.73% stake in the clinical-stage biotechnology company. This move, disclosed via a 13DG filing, signals a calculated, long-term commitment despite Upstream Bio's early-stage, pre-revenue status and recent stock decline. The investment suggests Norges Bank is making a high-risk, high-reward bet on the success of Upstream Bio's lead candidate, verekitug, for inflammatory diseases.

    GuruFocus•8/19/26•
    Somewhat-Bullish

    Walleye Capital LLC Invests $3.45 Million in Upstream Bio, Inc. $UPB

    Walleye Capital LLC has invested $3.45 million in Upstream Bio (NASDAQ:UPB), acquiring a 0.92% stake. This investment comes as Upstream Bio continues to be unprofitable, though it recently beat earnings and revenue estimates. Analyst sentiment is mixed, with a consensus "Hold" rating despite varying buy and sell recommendations and a projected full-year loss.

    MarketBeat•8/15/26•
    Neutral

    Upstream Bio (NASDAQ:UPB) Lowered to "Strong Sell" Rating by Wall Street Zen

    Wall Street Zen has downgraded Upstream Bio (NASDAQ:UPB) to a "Strong Sell" rating from "Sell," intensifying cautious sentiment around the clinical-stage biotech company. Despite the downgrade, analyst opinions remain mixed, with four "Buy" ratings, two "Hold," and one "Sell," resulting in a consensus "Hold" rating and an average price target of $29.67. Upstream Bio shares are trading near their 52-week low, and the company continues to report losses, although it slightly beat recent quarterly EPS and revenue estimates.

    MarketBeat•8/15/26•
    Bearish

    Upstream Bio (NASDAQ:UPB) Given New $9.00 Price Target at JPMorgan Chase & Co.

    JPMorgan Chase & Co. has raised its price target for Upstream Bio (NASDAQ:UPB) to $9.00 from $8.00, maintaining a "neutral" rating. This new target suggests a potential upside of 29.22% from the stock's current price of $6.96. The company recently reported a quarterly loss of $0.73 per share, beating analyst estimates, and revenue of $0.77 million, exceeding expectations.

    MarketBeat•8/14/26•
    Somewhat-Bullish

    Truist Financial Maintains UpStream Bio(UPB.US) With Buy Rating, Maintains Target Price $25

    Truist Financial has reiterated its Buy rating for UpStream Bio (UPB.US) and maintained its target price at $25. This indicates the firm's continued positive outlook on the company's stock performance.

    Moomoo•8/13/26•
    Bullish

    Frequently Asked Questions About UPB

    Does UPB pay dividends?
    Upstream Bio, Inc. (UPB) does not currently pay a regular dividend.
    What is UPB's market cap?
    Upstream Bio, Inc. (UPB) has a market capitalization of $366.42M with a current stock price of $6.62.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In